Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Podzamczer

Showing results (161-170 of 181) with videos related to

Pageof 19
Sort By:
Journal of Acquired Immune Deficiency Syndromes (1999)|November 16, 2006
Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized studyDaniel Podzamczer, Elena Ferrer, Pochita Sanchez, et al.
Neurology|June 8, 2014
Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditionsEllen C Caniglia, Lauren E Cain, Amy Justice, et al.
AIDS (London, England)|April 2, 2019
Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trialsSamir K Gupta, Frank A Post, José R Arribas, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|June 29, 2021
Prevalence and factors associated with SARS-CoV-2 seropositivity in the Spanish HIV Research Network CohortJuan Berenguer, Cristina Díez, María Martín-Vicente, et al.
The Lancet. Infectious Diseases|October 13, 2011
Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study, , Dominique Costagliola, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|January 31, 2007
[Spanish cohort of naïve HIV-infected patients (CoRIS): rationale, organization and initial results]Ana María Caro-Murillo, Jesús Castilla, Santiago Pérez-Hoyos, et al.
Lancet (London, England)|July 29, 2017
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trialDavid A Margolis, Juan Gonzalez-Garcia, Hans-Jürgen Stellbrink, et al.
Open Forum Infectious Diseases|September 24, 2021
Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 StudyGraham H R Smith, W Keith Henry, Daniel Podzamczer, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 29, 2009
A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppressionEsteban Martínez, José A Arranz, Daniel Podzamczer, et al.
The Journal of Antimicrobial Chemotherapy|September 19, 2023
Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimensDaniel Podzamczer, Arkaitz Imaz, Ana Lopez-Lirola, et al.
Pageof 19

Showing results (161-170 of 181) with videos related to

Sort By:
Pageof 19
Journal of Acquired Immune Deficiency Syndromes (1999)|November 16, 2006
Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized studyDaniel Podzamczer, Elena Ferrer, Pochita Sanchez, et al.
Neurology|June 8, 2014
Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditionsEllen C Caniglia, Lauren E Cain, Amy Justice, et al.
AIDS (London, England)|April 2, 2019
Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trialsSamir K Gupta, Frank A Post, José R Arribas, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|June 29, 2021
Prevalence and factors associated with SARS-CoV-2 seropositivity in the Spanish HIV Research Network CohortJuan Berenguer, Cristina Díez, María Martín-Vicente, et al.
The Lancet. Infectious Diseases|October 13, 2011
Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study, , Dominique Costagliola, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|January 31, 2007
[Spanish cohort of naïve HIV-infected patients (CoRIS): rationale, organization and initial results]Ana María Caro-Murillo, Jesús Castilla, Santiago Pérez-Hoyos, et al.
Lancet (London, England)|July 29, 2017
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trialDavid A Margolis, Juan Gonzalez-Garcia, Hans-Jürgen Stellbrink, et al.
Open Forum Infectious Diseases|September 24, 2021
Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 StudyGraham H R Smith, W Keith Henry, Daniel Podzamczer, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 29, 2009
A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppressionEsteban Martínez, José A Arranz, Daniel Podzamczer, et al.
The Journal of Antimicrobial Chemotherapy|September 19, 2023
Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimensDaniel Podzamczer, Arkaitz Imaz, Ana Lopez-Lirola, et al.
Pageof 19